RYTM Rhythm Pharmaceuticals, Inc.
RYTM Rhythm Pharmaceuticals, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-23 1 neutral converging
POC $89.41 · VWAP $99.18 · -10.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP, Officer + 2 others sold $17M, Aug 14–17
Coverage
1 watchlist
RYTM Price Structure
Loading timeframes…
Peers
Every watchlist RYTM belongs to, members best 30-day change first — RYTM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
Reported the quarter ending 2026-06-30: revenue $71M, diluted EPS -$0.73, net income -$49M (SEC filing). Across the print the stock moved +7.7% (close before → first close after).
full note →Against street estimates
How RYTM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about RYTM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 6 days ago · Oct 17
- RYTM.B - | Stock Price & Latest News
- Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Report
- Investor Overview – Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update – Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Q2 2026 Earnings Results & Report
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
RYTM research tape
60 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.